Stock Quote
Celgene Corporation (CELG.O) (Nasdaq)
$55.65
23 Nov 2009
+1.35%
$55.65
--
2,951,221
$55.87
$54.98
$58.31
$36.90
0.51
3,251,011
CELG.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Barer, Sol | Chairman of the Board, Chief Executive Officer | 8,525,090 |
| Hugin, Robert | President, Chief Operating Officer, Director | 5,158,400 |
| Gryska, David | Chief Financial Officer, Senior Vice President | 2,138,500 |
Profile
Celgene Corporation is an integrated biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is involved in research in several scientific areas that may deliver... Full Description
Company Address
Celgene Corporation
86 Morris Avenue
Summit NJ 07901
P: +1908.6739000
F: +1732.2714184
86 Morris Avenue
Summit NJ 07901
P: +1908.6739000
F: +1732.2714184
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Amgen, Inc. | $56.25 | +0.87 |
| AstraZeneca plc | £2,741.50 | +9.50 |
| Biogen Idec Inc. | $46.79 | +0.41 |
| CELG.O | Industry | |
|---|---|---|
| P/E(TTM) | 70.55 | 12.80 |
| P/S(TTM) | 10.00 | 29.90 |
| ROI(TTM) | 8.78 | 2.35 |
| ROE(TTM) | 9.70 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.61 |
| EPS Est. (Current Year) | 2.04 |
| Total Revenue | $695.14M |
| Net Income | $216.82M |
| EPS | $0.46 |
